Cumberland to present clinical trial data of Caldolor at the AAPM annual meeting

Cumberland Pharmaceuticals Inc.Oct 5 2009

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that data from two key clinical trials for Caldolor®, an intravenous formulation of ibuprofen approved for treatment of pain and fever in adults, will be presented at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting to be held in Phoenix, Ariz., on October 8-11, 2009.

Data from the following clinical trials of Caldolor will be displayed in poster presentations on Saturday, October 10, 2009, from 1:30-3:00 pm Mountain Time:

• A phase III dose ranging pain study entitled "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Intravenous Ibuprofen for the Management of Postoperative Pain in Adults" will be presented by principal author, Stephen R. Southworth, MD, FACS (study 008A, poster #49).
• A phase III abdominal hysterectomy pain study entitled "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Intravenous Ibuprofen for the Management of Postoperative Pain in Adults," authored by Peter Kroll, M.D., will be presented by co-author Laura Meadows, BC, CRCC (study 008B, poster #50).

In conjunction with the presentations, copies of the posters will be available on Cumberland's website at http://investor.shareholder.com/cpix/events.cfm, or by contacting the Company at 615-255-0068.